Cypherpunk Technologies Inc. (CYPH) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on August 12, 2026, by Cypherpunk Technologies Inc., a Delaware corporation. The filing primarily serves to announce financial results for the quarter ended June 30, 2026, and to report a significant scientific milestone for its biotechnology subsidiary, Leap Therapeutics, Inc.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the body of this report.
Material Changes and Events
- Financial Results: The Company announced its financial results for the quarter ended June 30, 2026, pursuant to Item 2.02.
- Scientific Milestone: Under Item 8.01, Leap Therapeutics, Inc. announced the publication of results from the randomized Phase 2 DeFianCe study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in the journal Clinical Cancer Research.
Guidance, Outlook, and Risks
The filing text does not contain specific forward-looking guidance, management commentary on future performance, or a detailed discussion of risks and contingencies. The report explicitly states that the information contained herein and in the accompanying exhibits shall not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2026 financial figures including revenue, net loss, and cash position.
- Examine Exhibit 99.2 for the full details of the Phase 2 DeFianCe study results for sirexatamab (DKN-01).
- Verify the impact of the study publication on the Company's development timeline and regulatory strategy.
- Confirm the Company's status as an emerging growth company and any associated reporting exemptions.